Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline left ventricular ejection fraction: a DAPA-MI substudy
Abstract Background Dapagliflozin improved cardiometabolic outcomes compared with placebo following acute myocardial infarction (MI) in participants without prior diabetes mellitus (DM) or chronic heart failure (HF) in the DAPA-MI trial. Purpose Cardiometabolic outcomes were assessed in the DAPA-MI...
Gespeichert in:
| Veröffentlicht in: | European heart journal 2024-10, Vol.45 (Supplement_1) |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | |
| container_title | European heart journal |
| container_volume | 45 |
| creator | Erlinge, D James, S Deanfield, J Eriksson, N De Belder, M Jones, D A Sederholm Lawesson, S Austin, D Szummer, K Ridderstrale, W Langkilde, A M Johansson, P A Mcguire, D K Oldgren, J Storey, R F |
| description | Abstract
Background
Dapagliflozin improved cardiometabolic outcomes compared with placebo following acute myocardial infarction (MI) in participants without prior diabetes mellitus (DM) or chronic heart failure (HF) in the DAPA-MI trial.
Purpose
Cardiometabolic outcomes were assessed in the DAPA-MI trial according to left ventricular ejection fraction (EF) at randomisation.
Methods
Participants were categorised according to whether baseline EF was ≥50 or |
| doi_str_mv | 10.1093/eurheartj/ehae666.1417 |
| format | Article |
| fullrecord | <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_eurheartj_ehae666_1417</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurheartj/ehae666.1417</oup_id><sourcerecordid>10.1093/eurheartj/ehae666.1417</sourcerecordid><originalsourceid>FETCH-LOGICAL-c897-d5872f9584cd7ad5b5612f22fa9d29ef898533e87fb24888ea87b53fe99ba9183</originalsourceid><addsrcrecordid>eNqNkMtOwzAQRS0EEqXwC8g_kDZOasdmV5VXpSJYdMEumjjj1lUaV7aDVL6FjyV9iDWrmbm6ZxaHkHuWjliq8jF2fo3g42aMa0AhxIhNWHFBBoxnWaLEhF-SQcoUT4SQn9fkJoRNmqZSMDEgP_PtDnSkztAadrBqrGnct22pa6kGX1u3xQiVa6ymrou6PwMFE9HT7d4dG9BQ2xrwOtoeAq1dH7YrGh2tIGBjW6QNmki_sI3e6q4BT3GDp77xcFweKNDH6cc0eZvT0FUhdvX-llwZaALeneeQLJ-flrPXZPH-Mp9NF4mWqkhqLovMKC4nui6g5hUXLDNZZkDVmUIjleR5jrIwVTaRUiLIouK5QaUqUEzmQyJOb7V3IXg05c7bLfh9ydLyoLj8U1yeFZcHxT3ITqDrdv9lfgHbz4ki</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline left ventricular ejection fraction: a DAPA-MI substudy</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Erlinge, D ; James, S ; Deanfield, J ; Eriksson, N ; De Belder, M ; Jones, D A ; Sederholm Lawesson, S ; Austin, D ; Szummer, K ; Ridderstrale, W ; Langkilde, A M ; Johansson, P A ; Mcguire, D K ; Oldgren, J ; Storey, R F</creator><creatorcontrib>Erlinge, D ; James, S ; Deanfield, J ; Eriksson, N ; De Belder, M ; Jones, D A ; Sederholm Lawesson, S ; Austin, D ; Szummer, K ; Ridderstrale, W ; Langkilde, A M ; Johansson, P A ; Mcguire, D K ; Oldgren, J ; Storey, R F</creatorcontrib><description><![CDATA[Abstract
Background
Dapagliflozin improved cardiometabolic outcomes compared with placebo following acute myocardial infarction (MI) in participants without prior diabetes mellitus (DM) or chronic heart failure (HF) in the DAPA-MI trial.
Purpose
Cardiometabolic outcomes were assessed in the DAPA-MI trial according to left ventricular ejection fraction (EF) at randomisation.
Methods
Participants were categorised according to whether baseline EF was ≥50 or <50%. Those without a baseline EF result and those who did not receive a dose of study drug were excluded. The primary objective was to determine the clinical effect of dapagliflozin 10 mg versus placebo assessed using a hierarchical composite outcome and analysed by the win ratio method. The primary outcome was the hierarchical composite, by order of perceived clinical importance, of death, hospitalization for HF (HHF), nonfatal MI, atrial fibrillation/flutter event, new diagnosis of type 2 DM, NYHA functional class at the last trial visit, and body weight decrease of ≥5% from baseline to the last trial visit. Time to first event of NYHA class II-IV or HHF and time to first event of NYHA class III-IV or HHF were assessed as endpoints of special interest. Hazard ratios (HR) with 95% confidence intervals (CI) were determined using Cox proportional hazards models. The main subgroup variable (baseline EF ≥50 or <50) and its interaction with treatment (P int) were included.
Results
838 participants had EF≥50 and 2913 had EF<50 at baseline. The primary hierarchical composite outcome resulted in a win ratio for those with EF≥50 of 1.32 (CI 1.00-1.73) and 1.38 for those with EF<50 (CI 1.21-1.57; P int 0.8) (Figures). There were no significant interactions by EF for any of the secondary outcomes. In those with EF<50, a first event of NYHA class II-IV or HHF occurred in 435 (29.4%) participants in the dapagliflozin group and 485 (33.8%) in the placebo group (absolute risk difference [ARD] 4.4%; HR 0.83, CI 0.73-0.94, P<0.01). In those with EF≥50, this occurred in 81 (19.7%) and 93 (21.8%), respectively (ARD 2.1%; HR 0.96, CI 0.65-1.41, P=0.7; P int 0.47). In those with EF<50, a first event of NYHA class III-IV or HHF occurred in 77 (5.2%) in the dapagliflozin and 115 (8.0%) in the placebo groups (ARD 2.2%; HR 0.64, CI 0.48-0.85, P<0.01). In those with EF≥50, this occurred in 14 (3.4%) and 19 (4.4%), respectively (ARD 1.0%; HR 0.80, CI 0.40-1.60, P=0.5; P int 0.55). There was no significant effect of dapagliflozin on death/MI/stroke in either subgroup (EF<50: HR 0.96, CI 0.65-1.41; EF≥50: HR 0.83, CI 0.38-1.84; P int 0.75). Dapagliflozin increased the incidence of 5% weight loss in both of the EF subgroups with no significant interaction.
Conclusions
Dapagliflozin resulted in significant benefit in cardiometabolic outcomes compared with placebo regardless of baseline EF. The absolute reduction in HF symptoms or HHF with dapagliflozin, compared with placebo, was greatest in those with baseline EF<50.Figures]]></description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehae666.1417</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>European heart journal, 2024-10, Vol.45 (Supplement_1)</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids></links><search><creatorcontrib>Erlinge, D</creatorcontrib><creatorcontrib>James, S</creatorcontrib><creatorcontrib>Deanfield, J</creatorcontrib><creatorcontrib>Eriksson, N</creatorcontrib><creatorcontrib>De Belder, M</creatorcontrib><creatorcontrib>Jones, D A</creatorcontrib><creatorcontrib>Sederholm Lawesson, S</creatorcontrib><creatorcontrib>Austin, D</creatorcontrib><creatorcontrib>Szummer, K</creatorcontrib><creatorcontrib>Ridderstrale, W</creatorcontrib><creatorcontrib>Langkilde, A M</creatorcontrib><creatorcontrib>Johansson, P A</creatorcontrib><creatorcontrib>Mcguire, D K</creatorcontrib><creatorcontrib>Oldgren, J</creatorcontrib><creatorcontrib>Storey, R F</creatorcontrib><title>Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline left ventricular ejection fraction: a DAPA-MI substudy</title><title>European heart journal</title><description><![CDATA[Abstract
Background
Dapagliflozin improved cardiometabolic outcomes compared with placebo following acute myocardial infarction (MI) in participants without prior diabetes mellitus (DM) or chronic heart failure (HF) in the DAPA-MI trial.
Purpose
Cardiometabolic outcomes were assessed in the DAPA-MI trial according to left ventricular ejection fraction (EF) at randomisation.
Methods
Participants were categorised according to whether baseline EF was ≥50 or <50%. Those without a baseline EF result and those who did not receive a dose of study drug were excluded. The primary objective was to determine the clinical effect of dapagliflozin 10 mg versus placebo assessed using a hierarchical composite outcome and analysed by the win ratio method. The primary outcome was the hierarchical composite, by order of perceived clinical importance, of death, hospitalization for HF (HHF), nonfatal MI, atrial fibrillation/flutter event, new diagnosis of type 2 DM, NYHA functional class at the last trial visit, and body weight decrease of ≥5% from baseline to the last trial visit. Time to first event of NYHA class II-IV or HHF and time to first event of NYHA class III-IV or HHF were assessed as endpoints of special interest. Hazard ratios (HR) with 95% confidence intervals (CI) were determined using Cox proportional hazards models. The main subgroup variable (baseline EF ≥50 or <50) and its interaction with treatment (P int) were included.
Results
838 participants had EF≥50 and 2913 had EF<50 at baseline. The primary hierarchical composite outcome resulted in a win ratio for those with EF≥50 of 1.32 (CI 1.00-1.73) and 1.38 for those with EF<50 (CI 1.21-1.57; P int 0.8) (Figures). There were no significant interactions by EF for any of the secondary outcomes. In those with EF<50, a first event of NYHA class II-IV or HHF occurred in 435 (29.4%) participants in the dapagliflozin group and 485 (33.8%) in the placebo group (absolute risk difference [ARD] 4.4%; HR 0.83, CI 0.73-0.94, P<0.01). In those with EF≥50, this occurred in 81 (19.7%) and 93 (21.8%), respectively (ARD 2.1%; HR 0.96, CI 0.65-1.41, P=0.7; P int 0.47). In those with EF<50, a first event of NYHA class III-IV or HHF occurred in 77 (5.2%) in the dapagliflozin and 115 (8.0%) in the placebo groups (ARD 2.2%; HR 0.64, CI 0.48-0.85, P<0.01). In those with EF≥50, this occurred in 14 (3.4%) and 19 (4.4%), respectively (ARD 1.0%; HR 0.80, CI 0.40-1.60, P=0.5; P int 0.55). There was no significant effect of dapagliflozin on death/MI/stroke in either subgroup (EF<50: HR 0.96, CI 0.65-1.41; EF≥50: HR 0.83, CI 0.38-1.84; P int 0.75). Dapagliflozin increased the incidence of 5% weight loss in both of the EF subgroups with no significant interaction.
Conclusions
Dapagliflozin resulted in significant benefit in cardiometabolic outcomes compared with placebo regardless of baseline EF. The absolute reduction in HF symptoms or HHF with dapagliflozin, compared with placebo, was greatest in those with baseline EF<50.Figures]]></description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqNkMtOwzAQRS0EEqXwC8g_kDZOasdmV5VXpSJYdMEumjjj1lUaV7aDVL6FjyV9iDWrmbm6ZxaHkHuWjliq8jF2fo3g42aMa0AhxIhNWHFBBoxnWaLEhF-SQcoUT4SQn9fkJoRNmqZSMDEgP_PtDnSkztAadrBqrGnct22pa6kGX1u3xQiVa6ymrou6PwMFE9HT7d4dG9BQ2xrwOtoeAq1dH7YrGh2tIGBjW6QNmki_sI3e6q4BT3GDp77xcFweKNDH6cc0eZvT0FUhdvX-llwZaALeneeQLJ-flrPXZPH-Mp9NF4mWqkhqLovMKC4nui6g5hUXLDNZZkDVmUIjleR5jrIwVTaRUiLIouK5QaUqUEzmQyJOb7V3IXg05c7bLfh9ydLyoLj8U1yeFZcHxT3ITqDrdv9lfgHbz4ki</recordid><startdate>20241028</startdate><enddate>20241028</enddate><creator>Erlinge, D</creator><creator>James, S</creator><creator>Deanfield, J</creator><creator>Eriksson, N</creator><creator>De Belder, M</creator><creator>Jones, D A</creator><creator>Sederholm Lawesson, S</creator><creator>Austin, D</creator><creator>Szummer, K</creator><creator>Ridderstrale, W</creator><creator>Langkilde, A M</creator><creator>Johansson, P A</creator><creator>Mcguire, D K</creator><creator>Oldgren, J</creator><creator>Storey, R F</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20241028</creationdate><title>Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline left ventricular ejection fraction: a DAPA-MI substudy</title><author>Erlinge, D ; James, S ; Deanfield, J ; Eriksson, N ; De Belder, M ; Jones, D A ; Sederholm Lawesson, S ; Austin, D ; Szummer, K ; Ridderstrale, W ; Langkilde, A M ; Johansson, P A ; Mcguire, D K ; Oldgren, J ; Storey, R F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c897-d5872f9584cd7ad5b5612f22fa9d29ef898533e87fb24888ea87b53fe99ba9183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Erlinge, D</creatorcontrib><creatorcontrib>James, S</creatorcontrib><creatorcontrib>Deanfield, J</creatorcontrib><creatorcontrib>Eriksson, N</creatorcontrib><creatorcontrib>De Belder, M</creatorcontrib><creatorcontrib>Jones, D A</creatorcontrib><creatorcontrib>Sederholm Lawesson, S</creatorcontrib><creatorcontrib>Austin, D</creatorcontrib><creatorcontrib>Szummer, K</creatorcontrib><creatorcontrib>Ridderstrale, W</creatorcontrib><creatorcontrib>Langkilde, A M</creatorcontrib><creatorcontrib>Johansson, P A</creatorcontrib><creatorcontrib>Mcguire, D K</creatorcontrib><creatorcontrib>Oldgren, J</creatorcontrib><creatorcontrib>Storey, R F</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Erlinge, D</au><au>James, S</au><au>Deanfield, J</au><au>Eriksson, N</au><au>De Belder, M</au><au>Jones, D A</au><au>Sederholm Lawesson, S</au><au>Austin, D</au><au>Szummer, K</au><au>Ridderstrale, W</au><au>Langkilde, A M</au><au>Johansson, P A</au><au>Mcguire, D K</au><au>Oldgren, J</au><au>Storey, R F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline left ventricular ejection fraction: a DAPA-MI substudy</atitle><jtitle>European heart journal</jtitle><date>2024-10-28</date><risdate>2024</risdate><volume>45</volume><issue>Supplement_1</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract><![CDATA[Abstract
Background
Dapagliflozin improved cardiometabolic outcomes compared with placebo following acute myocardial infarction (MI) in participants without prior diabetes mellitus (DM) or chronic heart failure (HF) in the DAPA-MI trial.
Purpose
Cardiometabolic outcomes were assessed in the DAPA-MI trial according to left ventricular ejection fraction (EF) at randomisation.
Methods
Participants were categorised according to whether baseline EF was ≥50 or <50%. Those without a baseline EF result and those who did not receive a dose of study drug were excluded. The primary objective was to determine the clinical effect of dapagliflozin 10 mg versus placebo assessed using a hierarchical composite outcome and analysed by the win ratio method. The primary outcome was the hierarchical composite, by order of perceived clinical importance, of death, hospitalization for HF (HHF), nonfatal MI, atrial fibrillation/flutter event, new diagnosis of type 2 DM, NYHA functional class at the last trial visit, and body weight decrease of ≥5% from baseline to the last trial visit. Time to first event of NYHA class II-IV or HHF and time to first event of NYHA class III-IV or HHF were assessed as endpoints of special interest. Hazard ratios (HR) with 95% confidence intervals (CI) were determined using Cox proportional hazards models. The main subgroup variable (baseline EF ≥50 or <50) and its interaction with treatment (P int) were included.
Results
838 participants had EF≥50 and 2913 had EF<50 at baseline. The primary hierarchical composite outcome resulted in a win ratio for those with EF≥50 of 1.32 (CI 1.00-1.73) and 1.38 for those with EF<50 (CI 1.21-1.57; P int 0.8) (Figures). There were no significant interactions by EF for any of the secondary outcomes. In those with EF<50, a first event of NYHA class II-IV or HHF occurred in 435 (29.4%) participants in the dapagliflozin group and 485 (33.8%) in the placebo group (absolute risk difference [ARD] 4.4%; HR 0.83, CI 0.73-0.94, P<0.01). In those with EF≥50, this occurred in 81 (19.7%) and 93 (21.8%), respectively (ARD 2.1%; HR 0.96, CI 0.65-1.41, P=0.7; P int 0.47). In those with EF<50, a first event of NYHA class III-IV or HHF occurred in 77 (5.2%) in the dapagliflozin and 115 (8.0%) in the placebo groups (ARD 2.2%; HR 0.64, CI 0.48-0.85, P<0.01). In those with EF≥50, this occurred in 14 (3.4%) and 19 (4.4%), respectively (ARD 1.0%; HR 0.80, CI 0.40-1.60, P=0.5; P int 0.55). There was no significant effect of dapagliflozin on death/MI/stroke in either subgroup (EF<50: HR 0.96, CI 0.65-1.41; EF≥50: HR 0.83, CI 0.38-1.84; P int 0.75). Dapagliflozin increased the incidence of 5% weight loss in both of the EF subgroups with no significant interaction.
Conclusions
Dapagliflozin resulted in significant benefit in cardiometabolic outcomes compared with placebo regardless of baseline EF. The absolute reduction in HF symptoms or HHF with dapagliflozin, compared with placebo, was greatest in those with baseline EF<50.Figures]]></abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/eurheartj/ehae666.1417</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0195-668X |
| ispartof | European heart journal, 2024-10, Vol.45 (Supplement_1) |
| issn | 0195-668X 1522-9645 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_eurheartj_ehae666_1417 |
| source | Oxford University Press Journals All Titles (1996-Current) |
| title | Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline left ventricular ejection fraction: a DAPA-MI substudy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T14%3A47%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20dapagliflozin%20on%20cardiometabolic%20outcomes%20after%20myocardial%20infarction%20according%20to%20baseline%20left%20ventricular%20ejection%20fraction:%20a%20DAPA-MI%20substudy&rft.jtitle=European%20heart%20journal&rft.au=Erlinge,%20D&rft.date=2024-10-28&rft.volume=45&rft.issue=Supplement_1&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehae666.1417&rft_dat=%3Coup_cross%3E10.1093/eurheartj/ehae666.1417%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/eurheartj/ehae666.1417&rfr_iscdi=true |